Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases
WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's
United States Proctitis Proctosigmoiditis Leo Ehrlich Innovation Pharmaceuticals Inc Company Brilacidin Phase Drug Administration
Source: finanznachrichten.de